Please visit answersincme.com/BUA860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in liver and biliary cancers discusses the clinical impact of immune checkpoint inhibitors in advanced biliary tract cancer. Upon completion of this activity, participants should be better able to: Recognize the clinical rationale for incorporating immune checkpoint inhibitor (ICI) plus chemotherapy combinations in the treatment of advanced biliary tract cancer; Describe the clinical impact of late-stage ICI plus chemotherapy combinations for the first-line treatment of advanced biliary tract cancer, in the context of conventional therapy options; and Outline clinical considerations for the future use of ICI plus chemotherapy combinations in the first-line treatment of advanced biliary tract cancer.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related